This study (2015) reviews the evidence on the neuropsychopharmacology of such substances as LSD, psilocybin, and mescaline.
Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.
Serotonergic hallucinogens — encompassing two main structural classes, the phenylalkylamines and the indoleamines — produce profound alterations in perception, thought, and mood and have been used by humans for thousands of years, though scientific investigation began only in the late nineteenth century. Defining hallucinogens as a pharmacological class proved contentious: standard definitions based on altered consciousness without delirium or addiction were insufficiently specific, leading to the proposal that, in addition to these properties, hallucinogens should bind to the 5-HT2A receptor and produce full substitution for the prototypical agent DOM in drug discrimination paradigms. Despite their structural heterogeneity, phenylalkylamine and indoleamine hallucinogens produce virtually indistinguishable subjective effects, show cross-tolerance with one another, and share a unifying pharmacological mechanism through 5-HT2A receptor activation. This review aimed to synthesise advances in understanding the neuropsychopharmacology of serotonergic hallucinogens, covering receptor pharmacology, validated animal behavioural models, tolerance and cross-tolerance, evidence from human experimental studies, and the role of the prefrontal cortex and its interactions with subcortical structures as a primary site of hallucinogenic drug action.
Papers cited by this study that are also in Blossom
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
This is a comprehensive narrative review that synthesised the preclinical and human experimental literature on serotonergic hallucinogens without formal inclusion/exclusion criteria or quantitative meta-analytic methods. The author covered receptor binding and functional pharmacology — including 5-HT2A and 5-HT2C subtype selectivity — drug discrimination studies using operant conditioning paradigms in rodents, the head twitch response (HTR) assay, prepulse inhibition of startle (PPI), interval timing paradigms, and locomotor activity measures. Human experimental evidence was drawn from challenge studies examining cross-tolerance and subjective effects across compounds. Neurobiological coverage focused on 5-HT2A receptor expression patterns across cortical layers and brain regions, electrophysiological recordings from prefrontal cortex pyramidal neurons in vitro and in vivo, and the organisation of cortico-striato-thalamo-cortical (CSTC) loop circuitry as a substrate for hallucinogen action.
Cross-tolerance studies confirmed that phenylalkylamine and indoleamine hallucinogens mutually substitute in drug discrimination paradigms and produce equivalent blunting of subjective effects following repeated dosing — evidence consistent with a shared receptor mechanism. Multiple converging lines of evidence from in vitro and in vivo work identified 5-HT2A receptor activation as the unitary mechanism responsible for hallucinogenesis: selective 5-HT2A antagonists block hallucinogenic behavioural effects in animals and subjective effects in humans, and highly selective phenylisopropylamine hallucinogens such as DOM produce full substitution for indoleamines in drug discrimination. Electrophysiological investigation identified the prefrontal cortex as a primary site of hallucinogen action. The 5-HT2A receptor is expressed densely in lamina V of the PFC on pyramidal neurons and parvalbumin-positive interneurons. Systemic hallucinogen administration in rats produced a net excitatory effect on PFC pyramidal neurons, with individual cells either excited (38–53%), inhibited (27–35%), or unresponsive. These PFC effects are thought to propagate through CSTC loops involving thalamo-cortical and striato-thalamic circuits to generate the broader pattern of perceptual and cognitive alterations characteristic of hallucinogen action.
Convergence of pharmacological, electrophysiological, and human experimental evidence leaves little scientific doubt that 5-HT2A receptor activation is the primary mechanism of classical hallucinogenesis, with the prefrontal cortex — and its dense laminar expression of the receptor on pyramidal neurons — constituting a critical neuroanatomical site of drug action. The net excitatory effect of hallucinogens on PFC pyramidal cells, propagated through CSTC circuitry, offers a plausible neural basis for the disorganised and amplified pattern of cortical activity associated with altered consciousness and perceptual distortion. The resumption of human research with hallucinogens — including brain imaging studies using fMRI, PET, and MEG — has provided additional support for animal and in vitro evidence, and is beginning to elucidate how receptor-level pharmacology translates into circuit-level and behavioural effects. The author identifies understanding of functional selectivity at the 5-HT2A receptor — specifically the relative contributions of G-protein and β-arrestin signalling pathways — as an important avenue for dissociating perceptual from therapeutic effects and for the rational design of functionally selective compounds.
The neuropsychopharmacology of serotonergic hallucinogens is increasingly well characterised: both phenylalkylamine and indoleamine classes produce their subjective and behavioural effects primarily through 5-HT2A receptor activation, with the prefrontal cortex and cortico-striato-thalamo-cortical circuits serving as the principal neuroanatomical substrates. Validated animal models — including drug discrimination, head twitch response, and prepulse inhibition paradigms — have provided essential tools for dissecting receptor mechanisms, and the resumption of controlled human studies is beginning to translate these preclinical insights into neuroimaging and clinical findings. Continued investigation of functional selectivity at the 5-HT2A receptor and the circuit-level consequences of PFC activation holds promise for developing a more complete account of hallucinogen pharmacology and informing the design of novel therapeutic agents.
Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E. et al. · Psychopharmacology (1999)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)
Carter, O. L., Hasler, F. ;., Pettigrew, J. D. et al. · Psychopharmacology (2007)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Moya, P. R., Berg, K. A., Gutiérrez-Hernandez, M. A. et al. · Journal of Pharmacology and Experimental Therapeutics (2007)
Páleníček, T., Fujáková, M., Brunovský, M. et al. · Psychopharmacology (2012)
Hoch, P. H., Cattell, J. P., Pennes, H. H. · American Journal of Psychiatry (1952)
Aronson, H., Silverstein, A. B., Klee, G. D. · JAMA Psychiatry (1980)
Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)
Gillin, J. C., Kaplan, J., Stillman, R. et al. · American Journal of Psychiatry (1976)
Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Bernasconi, F. ;., Schmidt, A. ;., Pokorny, T. ;. et al. · Cerebral Cortex (2013)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Papers in Blossom that reference this study
Irrmischer, M., Aqil, M., Luan, L. et al. · Journal of Neuroscience (2025)
Aqil, M., De Hollander, G., Vreugdenhil, N. et al. · Biorxiv (2025)
Palmisano, V. F., Agnorelli, C., Fagiolini, A. et al. · Biochemistry (2024)
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Tyagi, R., Saraf, T. S., Canal, C. E. · ACS Pharmacology and Translational Science (2023)
Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)
Romeo, B., Fauvel, B., Verroust, V. et al. · Journal of Psychoactive Drugs (2023)
Prugger, J., Hirschfeld, T., Majic, T. et al. · Neuropsychopharmacology (2023)
Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Császár, N., Bob, P., Bókkon, I. · Journal of Integrative Neuroscience (2022)
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A. et al. · Biomedicine & Pharmacotherapy (2022)
Yu, C. L., Liang, C. S., Yang, F. et al. · Journal of Clinical Medicine (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Barker, S. A. · Psychopharmacology (2022)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
James Perez Custodio, R., Ortiz, D. M., Lee, H. J. et al. · SSRN (2022)
Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)
Vejmola, Č., Tylš, F., Piorecká, V. et al. · Translational Psychiatry (2021)
Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)
Leptourgos, P., Bouttier, V., Denève, S. et al. · Psyarxiv (2021)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)
Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)
Ortiz, M. I., Gómez-Busto, F. J. · Clinical Neuropsychiatry (2020)
Klein, A. K., Chatha, M., Laskowski, L. J. et al. · ACS Pharmacology and Translational Science (2020)
Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)
Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)
Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)
Dipasquale, O., Selvaggi, P., Veronese, M. et al. · NeuroImage (2019)
Libânio Osório Marta, R. F. · Drug Metabolism Reviews (2019)
Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)
Deco, G., Cruzat, J., Cabral, J. et al. · Current Biology (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Cameron, L. P. · ACS Chemical Neuroscience (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
Kaelen, M. · Imperial College London (2017)
Bryson, A., Carter, O., Norman, T. et al. · International Journal of Neuropsychopharmacology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Halberstadt, A. L. · Current Topics in Behavioral Neurosciences (2017)
López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Canal, C. E., Murnane, K. S. · Journal of Psychopharmacology (2016)
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Roseman, L., Sereno, M. I., Leech, R. et al. · Human Brain Mapping (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Halberstadt, A. L. · Pharmacology Biochemistry and Behavior (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)